42746-49-6

Upstream product

• 4436-24-2 1,2-epoxy-3-phenylpropane 
• 51-79-6 urethane 
• 108-86-1 bromobenzene 
• 131118-90-6 (+/-)-benzyl (oxiran-2-ylmethyl)carbamate 
• 50411-26-2 3-phenyl-2-hydroxypropylamine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 598-55-0 methyl carbamate 
• 68395-97-1 2-hydroxy-3-phenylpropyl phenyl selenide 
• 62825-83-6 3-benzoyl-5-benzyl-oxazolidin-2-one 

Downstream Products

• 62825-80-3 3-acetyl-5-benzyl-oxazolidin-2-one 
• 62825-82-5 (±)-N-benzyl-5-benzyloxazolidin-2-one 
• 62825-79-0 5-benzyl-3-methyl-oxazolidin-2-one 
• 62825-83-6 3-benzoyl-5-benzyl-oxazolidin-2-one 
• 62825-84-7 5-benzyl-3-(2-dimethylamino-ethyl)-oxazolidin-2-one 
• 62825-85-8 5-benzyl-3-(3-dimethylamino-propyl)-oxazolidin-2-one 
• 62825-81-4 5-benzyl-3-propyl-oxazolidin-2-one 
• 42746-50-9 5-benzyl-3-nitroso-oxazolidin-2-one 

Relevant academic research and scientific papers

AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS

The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the treatment or prevention of various diseases, conditions or disorders.

Nickel-catalyzed regiodivergent opening of epoxides with aryl halides: Co-catalysis controls regioselectivity

Epoxides are versatile intermediates in organic synthesis, but have rarely been employed in cross-coupling reactions. We report that bipyridine-ligated nickel can mediate the addition of functionalized aryl halides, a vinyl halide, and a vinyl triflate to epoxides under reducing conditions. For terminal epoxides, the regioselectivity of the reaction depends upon the cocatalyst employed. Iodide cocatalysis results in opening at the less hindered position via an iodohydrin intermediate. Titanocene cocatalysis results in opening at the more hindered position, presumably via TiIII-mediated radical generation. 1,2-Disubstituted epoxides are opened under both conditions to form predominantly the trans product.

GSK-3BETA INHIBITOR

For the purpose of providing a GSK-3β inhibitor containing a 2-aminopyridine compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (IA): wherein each symbol is as defined in the specification. or a salt thereof or a prodrug thereof.

A facile one-pot solid-phase synthesis of oxazolidin-2-ones using polymer-supported 2-hydroxyalkyl selenide reagent

A simple, efficient and environmentally friendly procedure for one-pot solid-phase synthesis of 2-oxazolidinones in moderate to good yields by reaction of polystyrene-supported 2-hydroxyalkyl selenide with benzoyl isocyanate and subsequent oxidation/cycli

Facile one-pot synthesis of oxazolidin-2-ones from phenyl 2-hydroxyalkyl selenides

A novel, convenient, efficient, three-step, one-pot synthesis of 2-oxazolidinones from phenyl 2-hydroxyalkyl selenides was developed. Using this methodology, 2-oxazolidinones are obtained in good yields (76-85%) by reaction of phenyl 2-hydroxyalkyl seleni

Therapeutic heterocyclic compounds

Compounds of formula (I) STR1 wherein R and R1 are hydrogen, C1-4 alkyl or are linked to form a ring, A is a cycloalkyl or alkyl-cycloalkyl group, n is an integer from 0 to 3, W is an optionally substituted 5-or 6-membered heterocycl

Indolyl tetrahydropyridines for treating migraine

STR1 The present invention is concerned with compounds of formula (I), wherein n is an integer of from 0 to 3: W is a group of formula (i), (ii), or (iii), wherein R is hydrogen or C1-4 alkyl, X is --O--, --S--, --NH--, or --CH2 --, Y is oxygen or sulphur and the chiral center (*) in formula (i) or (ii) is in its (S) or (R) form or is a mixture thereof in any proportions: and Z is a group of formula (iv), (v), or (vi), wherein R1 and R2 are independently selected from hydrogen and C1-4 alkyl and R3 is hydrogen or C1-4 alkyl; and their salts, solvates and physiologically functional derivatives, with processes for their preparation, with medicaments containing them and with their use as therapeutic agents, particularly in the prophylaxis and treatment of migraine.

5-Benzyl-2-oxazolidone derivatives and a process for producing the same

5-Benzyl-2-oxazolidone derivatives of the formula: STR1 wherein R1 represents a hydrogen, halogen, lower alkyl, trihalogenomethyl, phenyl, benzyl, hydroxy, lower alkoxy, phenoxy, benzyloxy, acyloxy, allyloxy, alkylcarbonyl, arylcarbonyl or alkylenedioxy group, and R2 represents a hydrogen atom, a lower alkyl, lower alkylcarbonyl, lower-dialkylamino-lower-alkyl, aryl, aralkyl or arylcarbonyl group.